Figures & data
Figure 1. Methylation status of CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 across 97 cancer cell lines. The six biomarkers have been analyzed by quantitative methylation-specific PCR (qMSP) in 97 different cancer cell lines originating from 17 tissues. Each cell line is represented by a square and the color scale indicates the percent of methylation reference (PMR) value. Abbreviations: MPNST, malignant peripheral nerve sheath tumor.
Figure 2. Percent promoter methylation of the analyzed genes in the sample series. The biomarker panel has been analyzed in control and tumor samples by quantitative methylation specific PCR (qMSP) in a test and validation series. Each dot represents one sample (lymphoma or control). Abbreviations: BL, Burkitt’s lymphoma; BM, Bone marrow; DLBCL ABC, activated B-cell like diffuse large B-cell lymphoma; DLBCL GCB, germinal center B-cell like diffuse large B-cell lymphoma; FH, follicular hyperplasia; FL, follicular lymphoma; PBMC, peripheral blood mononuclear cells; PMBL, primary mediastinal B-cell lymphoma; PMR, percent methylated reference.
Table 1. Methylation frequencies assessed by qMSP in the test and validation series
Figure 3. Receiver Operating Characteristics (ROC) curves for individual and combined markers in lymphoma patients vs. healthy donors. The area under the ROC curve (AUC; A) represents how accurate the individual and combined biomarkers can discriminate between lymphomas and normal samples. (A) Lymphoma patients vs. healthy donors for individual genes. (B) Lymphoma patients vs. healthy donors for the genes SNCA and SPG20. (C) DLBCL ABC (activated B-cell like diffuse large B-cell lymphoma) and GCB (germinal center B-cell like diffuse large B-cell lymphoma) vs. PMBL (primary mediastinal B-cell lymphoma) for the MAL gene.
Figure 4.CNRIP1 methylation status has prognostic value in DLBCL ABC (activated B-cell like diffuse large B-cell lymphoma) and GCB (germinal center B-cell like diffuse large B-cell lymphoma). The overall survival was analyzed using the Kaplan-Meier-method and the log-rank test. Survival was calculated in months from date of diagnosis to last follow up.
